Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03985384 · ClinicalTrials.gov registry record · Phase 4
Semaglutide Treatment On Coronary Progression
A Phase 4 study, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 140
- Enrollment target
NCT03985384 is a Phase 4 study that has completed, run by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The registered enrollment target is 140 participants.
The verdict
NCT03985384, a Phase 4 study, has completed, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 140 participants
- Enrollment target
Study Summary
The purpose of this research study is to see the effect of the diabetes medicine Semaglutide on a condition called atherosclerosis. Atherosclerosis is a narrowing, blockage, or hardening of the arteries due to a build up of calcium. This study will look specifically at the arteries involving the heart.
Interventions
- DRUG Placebo
- DRUG Semaglutide 2 MG/1.5 ML Subcutaneous Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2019-04-30 |
| Est. Completion | 2022-12-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03985384
The ClinicalTrials.gov registry entry for NCT03985384 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03985384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03985384 about?
NCT03985384 is a clinical study titled "Semaglutide Treatment On Coronary Progression". The purpose of this research study is to see the effect of the diabetes medicine Semaglutide on a condition called atherosclerosis. Atherosclerosis is a narrowing, blockage, or hardening of the arteries due to a build up of calcium. This study will look specifically at the arteries involving the hea...
What is the current status of trial NCT03985384?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 140 participants. The study started on 2019-04-30. Estimated completion is 2022-12-27.
What interventions are being tested in trial NCT03985384?
The interventions under investigation include: Placebo (DRUG), Semaglutide 2 MG/1.5 ML Subcutaneous Solution (DRUG).
Who is sponsoring clinical trial NCT03985384?
This trial is sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.